FDA Clears Pfizer’s Braftovi + Mektovi for Non-Small Cell Lung Cancer Treatment

Published on: 

Treatment indicated for patients with BRAF V600E-mutant metastatic form of disease.

Pfizer revealed that the FDA has approved Braftoni (encorafenib) + Mektovi (binimetinib) for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation. Previously, the medication was approved for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation.


“Today’s approval builds on our long-standing commitment to deliver innovative, personalized medicines to patients with lung cancer. By pursuing precision medicines that target a patient’s specific type of cancer, we are leveraging our deep understanding of tumor biology to help address the underlying cause of disease,” said Chris Boshoff, MD, PhD, chief oncology research and development officer, EVP, Pfizer. “Since its initial FDA approval in 2018, Braftovi + Mektovi combination therapy has helped thousands of people living with BRAF V600E- or V600K-mutant unresectable or metastatic melanoma.2 We look forward to helping even more patients with our Braftovi+ Mektovi targeted combination therapy.”

Reference: US FDA Approves Pfizer’s BRAFTOVI + MEKTOVI for BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer. Pfizer. October 12, 2023. Accessed October 12, 2023. https://www.pfizer.com/news/press-release/press-release-detail/us-fda-approves-pfizers-braftovir-mektovir-braf-v600e